CHARLESTON, SC – Just last November, the American College of Cardiology (ACC) and American Heart Association (AHA) published new clinical guidelines for the management of cholesterol, and the ...

Elderly patients with atherosclerotic cardiovascular disease (ASCVD) treated long-term with the PCSK9 inhibitor evolocumab (Repatha; Amgen) derive as much clinical benefit as younger people, according ...

People whose LDL cholesterol is in the normal range—even those without metabolic risk factors—may yet have levels of apolipoprotein B (apoB) that predict an elevated risk of future atherosclerotic ...

The path to atherosclerotic cardiovascular disease (ASCVD) often starts in youth, as significantly abnormal lipid levels typically track into adulthood and lay the groundwork for clinical events in ...

Higher levels of lipoprotein(a) (Lp[a]) were found to be associated with a continuously increasing risk of recurrent atherosclerotic cardiovascular disease (ASCVD) events. A new analysis of the Family ...

LONDON — Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death globally despite many advances in its diagnosis and management. Improving the understanding of the disease has ...

Salk scientists have tracked the flow of trans fats using mouse models to describe the molecular mechanisms that cause trans fats to promote atherosclerotic cardiovascular disease (ASCVD), explaining ...